Consensus CSL Limited Deutsche Boerse AG

Stocks

CSJA

US12637N2045

Pharmaceuticals

Market Closed - Deutsche Boerse AG Other stock markets 02:08:01 2026-06-18 EDT			5-day change	1st Jan Change
14.90 ^EUR	+2.05%		+5.67%	-37.39%

06-18	Moderna's mRNA flu vaccine backed by FDA advisers	RE
06-15	Global drugmakers invest billions to boost US presence	RE

Evolution of the Average Target: CSL Limited

Evolution of the Target Price: CSL Limited

Changes in Analyst Recommendations: CSL Limited

d3.YaJMR9HmnJV-3v6KFr6GEo6cqQX80Y8XALx1Iwt5wB0.PskDKua_y-YIhKzgL-vvK7fI8DPEmrYjbsgedz4VrmUbkyAE5aLbwxeRvw~2c84c77be5c67f784f2b11c8ad2b95d2

Analysts' recommendations: CSL Limited

05-11	CSL's Fiscal-Year Earnings Guidance Downgrade Not Surprising, Jefferies Says	MT
03-20	CSL's Business Not Threatened by CIDP Therapy Competition, Says Jefferies	MT
03-01	Organic Growth in Australia's Healthcare Services Likely Due to Increased Availability of Bulk-Billing General Practitioners, Jefferies Says	MT
02-10	CSL's Fiscal H1 EBIT Boosted by Cost Reductions, Jarden Says	MT
12-08	CSL's China Albumin Sale to Improve in Fiscal H2 2026, Says Jefferies	MT
11-10	CSL Impacted by Launch Delays, Vaccine Fatigue, Says Jefferies	MT
11-06	CSL Expected to See Potential Medium-Term Earnings Upside, Says Jefferies	MT
11-06	CSL's Horizon 2 Approach to 'Significantly' Boost Margins, Earnings, Jarden Says	MT
25-10-29	Jarden Research Adjusts CSL's Price Target to AU$287.14 from AU$304.17, Keeps at Overweight	MT
25-10-28	CSL Faces Macroeconomic Challenges, Will Take Time to Rerate, Says Jefferies, Shares Down 3%	MT
25-10-28	Canaccord Genuity Upgrades CSL to Buy from Hold; Price Target is AU$225	MT
25-10-28	CSL's Flu Revenue Impact for Northern Hemisphere Season Drives Guidance Downgrade, Jarden Says	MT
25-10-02	CSL to Benefit From Immunoglobin Sales Growth, Says Jefferies	MT
25-07-31	Carlisle Faces Downgrade From Loop Capital; Shares Fall	MT
25-07-11	CSL Shares Fall Amid Target Price Cut by Morgans Financial	MT
25-07-10	Morgans Financial Upgrades CSL to Buy from Add; Price Target is AU$303.70	MT
24-10-24	CSL's R&D Day "Uninspiring," Jarden Research Says	MT
24-09-08	CSL 'Strong Franchise in Medium Term' Amid Higher Fiscal 2024 Earnings, Jefferies Says	MT
24-09-04	Carlisle Expected to Show Solid Growth, Margin Expansion, Oppenheimer Says	MT
24-08-14	Jarden Research Adjusts CSL's Price Target to AU$329.62 From AU$305.34, Keeps at Overweight	MT
24-03-05	Morgan Stanley Adjusts CSL’s Price Target to AU$310 From AU$318, Keeps at Overweight	MT
24-02-13	Jarden Research CSL’s Price Target to AU$296.02 From AU$298.57, Keeps at Overweight	MT
24-02-12	Jarden Research Adjusts CSL’s Price Target to AU$298.57 From AU$316.16, Keeps at Overweight	MT
22-11-02	Arcturus Therapeutics Shares Rise 31% After Vaccine Collaboration	DJ

More recommendations

Sector Comparison:

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
CSL LIMITED	-	-	-	-
REGENERON PHARMACEUTICALS, INC.				+37.07%
UCB				+15.87%
SAMSUNG BIOLOGICS CO.,LTD.				+53%
BIOGEN INC.				+10.8%
MODERNA, INC.				-29.94%
INCYTE CORPORATION				+10.46%
INNOVENT BIOLOGICS, INC.				+57.05%
SWEDISH ORPHAN BIOVITRUM AB				+7.1%
BRIDGEBIO PHARMA, INC.				+51.77%
Average				+23.69%
Weighted average by Cap.				+24.84%